Clinical trials: Withdrawal Syndrome
Opioid Use Disorder
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
This study is examining the use of Tezampanel (TZP) for treatment of Opioid Withdrawal Syndrome (OWS) in participants with Opioid Use Disorder (OUD).
- Trial name
- NCT06538558
- Testing
- Tezampanel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Proniras Corporation
Safety and Pharmacokinetics of Intravenous Baclofen
Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers
The objective of this study is to determine safety and characterize pharmacokinetics of higher doses of intravenous baclofen in healthy subjects.
- Trial name
- NCT01931319
- Testing
- Intravenous baclofen
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Substance Withdrawal Syndrome
Effect of Ondansetron for Withdrawal Symptoms
We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications.
- Trial name
- NCT00695864
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Stanford University
Drug-withdrawal., Drug Abuse
Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts.
INTRODUCTION. One of the main problems of the treatment of cocaine-dependent patients is the high rate of relapses occurs within the first months after detoxification.
- Conditions
- Drug-withdrawal., Drug Abuse, Drug-induced Depressive State, AOD Craving
- Trial name
- MADC (NCT01949571)
- Testing
- Mirtazapine (REMERON, Schering-Plough-Organon)
- Where
- Mexico
- Volunteers
- 64 people
- Sponsor
- Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Iatrogenic Withdrawal Syndrome
Jackson Pediatric Acupressure for Opioid Tapering
This intervention pilot feasibility study will assess the impact of auricular acupressure as an additional non-pharmacologic therapy for infants at risk for developing Iatrogenic Withdrawal Syndrome (IWS) in the Pediatric Cardiac…
- Trial name
- NCT05025384
- Testing
- Acupressure
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
Sleep Apnea, Obstructive, Endothelial Dysfunction
Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal
Obstructive sleep apnea hypopnea syndrome (OSAS) is a frequent disease with neuropsychological and cardiovascular (CV) consequences.
- Trial name
- ORTAP (NCT05939934)
- Testing
- Mandibular advancement device treatment
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Angers
Opiate Withdrawal Syndrome
Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts
This is an open-label, randomized, 2-sequence, cross-over study evaluating the difference of efficacy between ear acupressure alone and ear acupressure plus electroacupuncture therapy both combined with methadone treatment…
- Trial name
- AAMTH (NCT03012373)
- Testing
- Ear acupressure alone, Electroacupuncture plus ear acupressure
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Lu-Tung Christian Hospital
Alcohol Withdrawal Syndrome
Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
Complicated alcohol withdrawal syndrome (AWS) increases morbidity and mortality of hospitalized, medically ill patients. The Psychosomatic Medicine Service is commonly consulted to assist in the management of these patients when…
- Trial name
- NCT05438641
- Testing
- BZDP-Sparing Protocol, BZDP-Based Protocol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Opioid-Related Disorders, Drug Addiction
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1).
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse
- Trial name
- MOMs-CMA (NCT03911466)
- Testing
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Where
- 12 sites in United States
- Volunteers
- 97 people
- Sponsor
- T. John Winhusen, PhD
Opioid-use Disorder, Opioid Withdrawal
Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
The primary objective of this trial is to determine whether tAN can improve relapse prevention beyond that seen with extended-release injectable naltrexone during Phase II.
- Trial name
- RESTORE (NCT05053503)
- Testing
- Sparrow Ascent Therapy System, Lofexidine, Extended-release injectable naltrexone
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Spark Biomedical, Inc.
Neonatal Opioid Withdrawal Syndrome, Neonatal Abstinence Syndrome
Neurostimulation to Improve NOWS Outcomes
The objective of this study is to determine if tAN therapy can reduce the median number of days of oral morphine administered to an infant after start of treatment.
- Trial name
- SPROUT (NCT05129020)
- Testing
- Sparrow Fledging Therapy System
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Spark Biomedical, Inc.
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity
Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group study of dexmedetomidine versus placebo, with lorazepam rescue, for the management of severe alcohol withdrawal syndrome (AWS) and alcohol…
- Conditions
- Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
- Trial name
- NCT01362205
- Testing
- Dexmedetomidine
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Denver Health and Hospital Authority
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Opiate Withdrawal Syndrome
Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal
The purpose of this study is to learn more about how the study drug, methadone, prescribed by an infant's or child's physician as part of standard medical care, is processed in children and young adults.
- Trial name
- MTH01 (NCT01945736)
- Testing
- Methadone
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Kevin Watt
Alcohol Withdrawal Syndrome, Alcohol Dependence
Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Gamma-Hydroxybutyric acid also known as sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results.
- Trial name
- GATE I (NCT02090504)
- Testing
- Sodium Oxybate (SMO), Oxazepam
- Where
- 3 sites in Austria, Italy
- Volunteers
- 127 people
- Sponsor
- Catholic University of the Sacred Heart
Neonatal Abstinence Syndrome
How to Treat Opiate Withdrawal in Neonates
Three different drugs are used in a randomised, double blind, clinical multi-centre trial with three arms. Major objective is to investigate the duration of drug treatment based on the Finnegan score.
- Trial name
- NCT02810782
- Testing
- Phenobarbital, Chlorpromazine, Morphine
- Volunteers
- 120 people
- Sponsor
- University of Zurich
Opioid-use Disorder, Opioid Withdrawal
Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
Clinical performance data for transcutaneous auricular neurostimulation (tAN) as a method to aid in the reduction of symptoms associated with opioid withdrawal in order to support clinical substantial equivalence to a predicate…
- Trial name
- NCT04075214
- Testing
- transcutaneous auricular neurostimulation (tAN)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Spark Biomedical, Inc.
Substance Withdrawal Syndrome
The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers
This study will evaluate the potential therapeutic value of two neurosteroid treatments (DHEA and pregnenolone) in the treatment of tobacco withdrawal symptoms.
- Trial name
- DHEA (NCT00900900)
- Testing
- dehydroepiandrosterone (DHEA), pregnenolone
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Jed E. Rose
Opioid-use Disorder, Opioid Withdrawal
Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
The objective of this study is to evaluate whether tAN via the tragus (vagal) and auriculotemporal (trigeminal) nerve pathways results in a clinically meaningful reduction in opioid withdrawal symptoms.
- Trial name
- NCT04731935
- Testing
- Sparrow Therapy System
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Spark Biomedical, Inc.
Obstructive Sleep Apnea
The Effects of Provent® on Obstructive Sleep Apnea During Continuous Positive Airway Pressure Therapy Withdrawal
Randomised, placebo-controlled trial of continuous positive airway pressure therapy (CPAP) versus Provent® and Placebo-Provent® to define the effects of Provent® on the severity of obstructive sleep apnea, daytime symptoms as…
- Trial name
- NCT01332175
- Testing
- Provent®, CPAP
- Where
- 3 sites in Switzerland, United Kingdom
- Volunteers
- 67 people
- Sponsor
- University of Zurich